Seeking to outpace the market, investors engage in the art of selecting individual stocks. The right picks can play a pivotal role in boosting your wealth.
As of close of business last night, Abbvie Inc’s stock clocked out at $223.98, down -0.53% from its previous closing price of $225.18. In other words, the price has decreased by -$0.53 from its previous closing price. On the day, 4.11 million shares were traded. ABBV stock price reached its highest trading level at $225.96 during the session, while it also had its lowest trading level at $222.24.
Ratios:
To gain a deeper understanding of ABBV’s stock, we examine its different ratios. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 69.80 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 20.11. For the most recent quarter (mrq), Quick Ratio is recorded 0.60 and its Current Ratio is at 0.72.
On November 13, 2025, Scotiabank started tracking the stock assigning a Sector Outperform rating and target price of $280. DZ Bank Downgraded its Buy to Hold on November 04, 2025, while the target price for the stock was maintained at $237.
Insider Transactions:
Investing in insider trades can also provide an investor with insight into how management views future stock prices. A recent insider transaction in this stock occurred on Aug 22 ’25 when Richard A. Gonzalez bought 62,755 shares for $210.84 per share.
Richard A. Gonzalez bought 90,000 shares of ABBV for $18,993,948 on Aug 21 ’25. On Aug 12 ’25, another insider, SALEKI-GERHARDT AZITA, who serves as the EVP, CHIEF OPERATIONS OFFICER of the company, sold 42,370 shares for $198.42 each. As a result, the insider received 8,407,055 and left with 177,292 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, ABBV now has a Market Capitalization of 395858804736 and an Enterprise Value of 459079811072. As of this moment, Abbvie’s Price-to-Earnings (P/E) ratio for their current fiscal year is 169.00, and their Forward P/E ratio for the next fiscal year is 15.67. The expected Price-to-Earnings-to-Growth (PEG) calculation for the next 5 years is 0.97. For the stock, the TTM Price-to-Sale (P/S) ratio is 6.64. Its current Enterprise Value per Revenue stands at 7.697 whereas that against EBITDA is 15.552.
Stock Price History:
The Beta on a monthly basis for ABBV is 0.35, which has changed by 0.291919 over the last 52 weeks, in comparison to a change of 0.14045572 over the same period for the S&P500. Over the past 52 weeks, ABBV has reached a high of $244.81, while it has fallen to a 52-week low of $164.39. The 50-Day Moving Average of the stock is -1.60%, while the 200-Day Moving Average is calculated to be 9.24%.
Shares Statistics:
It appears that ABBV traded 5.99M shares on average per day over the past three months and 4673020 shares per day over the past ten days. A total of 1.77B shares are outstanding, with a floating share count of 1.77B. Insiders hold about 0.09% of the company’s shares, while institutions hold 74.67% stake in the company. Shares short for ABBV as of 1764288000 were 18209156 with a Short Ratio of 3.04, compared to 1761868800 on 18891139. Therefore, it implies a Short% of Shares Outstanding of 18209156 and a Short% of Float of 1.0299999.
Dividends & Splits
With its trailing 12-month dividend rate of 6.56, ABBV has a forward annual dividend rate of 6.56. Against a Trailing Annual Dividend Yield of 0.02913225. The stock’s 5-year Average Dividend Yield is 3.75.
Earnings Estimates
The dynamic stock of Abbvie Inc (ABBV) is currently being evaluated by a team of 19.0 analysts, each contributing to its current rating.The consensus estimate for the next quarter is $3.05, with high estimates of $3.3 and low estimates of $2.84.
Analysts are recommending an EPS of between $10.83 and $10.5 for the fiscal current year, implying an average EPS of $10.64. EPS for the following year is $14.25, with 29.0 analysts recommending between $15.43 and $13.26.
Revenue Estimates
In. The current quarter, 18 analysts expect revenue to total $16.4B. It ranges from a high estimate of $17.01B to a low estimate of $16.23B. As of. The current estimate, Abbvie Inc’s year-ago sales were $15.1BFor the next quarter, 18 analysts are estimating revenue of $14.7B. There is a high estimate of $15.2B for the next quarter, whereas the lowest estimate is $14.45B.
A total of 28 analysts have provided revenue estimates for ABBV’s current fiscal year. The highest revenue estimate was $61.55B, while the lowest revenue estimate was $60.5B, resulting in an average revenue estimate of $60.94B. In the same quarter a year ago, actual revenue was $56.33BBased on 28 analysts’ estimates, the company’s revenue will be $66.64B in the next fiscal year. The high estimate is $68.7B and the low estimate is $65.31B.
